1

Ambrx Inc

Oncology

www.ambrx.com

HBM contact: Dr Emil Bujak

Company status: private

Ambrx develops breakthrough protein therapeutics using an expanded genetic code which is harnessed for site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders. This gives rise to a single molecular species that is optimized for safety, efficacy and biophysical properties. Using this proprietary technology Ambrx can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. This allows for a safe and effective targeting of cytotoxic agents or for recruitment of effector functions to tumor cells (oncology) or for modulation of biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171